Arachnova Ltd.

Crunched credit wiped out many biotech firms in 2009, yet some emerged from the wreckage leaner and stronger. How did they do it, asks Dr Sukaina Virji-Jeganathan. Despite hints of the emergence of g

The repositioning of drugs for new clinical indications is becoming an increasingly prominent development strategy because it can reduce development risk as well as both the time and investment requir

The Food and Drug Administration's intimation to Eli Lilly & Co. in late January that the regulator wouldn't approve Lilly's serotonin and norepinephrine reuptake inhibitor (SNRI) duloxetine as a t

Modulating ion channels via accessory proteins PO Box 2299 Bristol BS99 5YG, UK Phone: (44) 117 928 8973 Fax: (44) 117 925 2659 Web Site: www.lectustherapeutics.com Contact: Roland Kozlowski, PhD,